{
    "componentChunkName": "component---src-templates-blog-post-js",
    "path": "/posts/206da594635011ecb4996f5ba193d428/",
    "result": {"data":{"allMysqlLists":{"edges":[{"node":{"title":"FDA authorizes first antiviral pill to treat COVID-19","status":1,"alt":"","src":"","source":"cbsnews","menu":"politics","local_src":"","load_img":"","img_url":"https://cbsnews3.cbsistatic.com/hub/i/r/2021/11/17/0410f3de-569d-4f09-b759-dc2856bf383f/thumbnail/640x360/ca5684142d297ecd0048057efc6d4ca3/cbsn-fusion-pfizer-seeks-authorization-of-its-covid-antiviral-pill-and-booster-shot-expansion-thumbnail-838284-640x360.jpg#","href":"https://www.cbsnews.com/news/pfizer-covid-pill-fda-authorization/","description":"Thousands of courses of Pfizer's pills could be available this month.","country":"us","create_time":"2021-12-22T09:56:32.000Z","content":"[\"The Food and Drug Administration announced Wednesday it has authorized Pfizer's antiviral pills to treat COVID-19 for emergency use, allowing limited use of the drug in Americans as young as 12 who are at \\\"high risk for progression to severe COVID-19.\\\"\", \"The new treatment option comes as doctors are facing a nationwide shortage of monoclonal antibodies to treat high-risk cases of the disease, with most formulas ineffective against the fast-spreading Omicron variant.\\u00a0\", \"Early data suggests Pfizer's pills, called Paxlovid, are effective against Omicron cases. The drugmaker says it works to block the ability of the virus to make copies of itself.\", \"\\\"This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19,\\\" the FDA's Dr. Patrizia Cavazzoni said in a statement on Wednesday.\\u00a0\", \"Pfizer first sought emergency use authorization for Paxlovid, which combines five days of tablets of its own oral antiviral nirmatrelvir with the HIV drug ritonavir, in November. The company said it was shown in clinical trials to cut the chances of hospitalization or death by 88% among adults at high-risk of severe COVID-19, compared to a placebo.\\u00a0\", \"\\\"This breakthrough therapy, which has been shown to significantly reduce hospitalizations and deaths and can be taken at home, will change the way we treat COVID-19, and hopefully help reduce some of the significant pressures facing our healthcare and hospital system,\\\" Pfizer's CEO Albert Bourla said in a release.\\u00a0\", \"Pfizer says it is ready to begin deliveries of Paxlovid in the U.S. immediately, supplying up to 10 million courses of the treatment through next year. However, only thousands \\u2013 not millions \\u2013 of courses of the drug are expected to be available this month, Bourla told The Wall Street Journal earlier this year.\\u00a0\", \"CBS News reporter covering public health and the pandemic.\"]","href_hash":"206da594635011ecb4996f5ba193d428"}}]}},"pageContext":{"slug":"206da594635011ecb4996f5ba193d428"}},
    "staticQueryHashes": ["3649515864","764694655"]}